TOP TEN perturbations for 1553506_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553506_at
Selected probe(set): 1553506_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553506_at (1553506_at) across 6672 perturbations tested by GENEVESTIGATOR:

Crohn's disease study 3 (baseline; non-responder; ileum) / normal ileum mucosa tissue

Relative Expression (log2-ratio):-4.574394
Number of Samples:10 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; ileum)
Ileal mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal ileum mucosa tissue
Ileal mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 3 (baseline; responder; ileum) / normal ileum mucosa tissue

Relative Expression (log2-ratio):-2.6265993
Number of Samples:8 / 6
Experimental Crohn's disease study 3 (baseline; responder; ileum)
Ileal mucosal biopsy derived from Crohn's disease patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal ileum mucosa tissue
Ileal mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)

Relative Expression (log2-ratio):1.6879911
Number of Samples:34 / 19
Experimental diabetes type 2 study 27 (LCM)
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year.
Control diabetes type 2 study 27 (enzymatic)
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies.

expO breast cancer study 1 (lobular carcinoma, NOS; primary) / expO breast cancer study 1 (lobular carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-1.324153
Number of Samples:39 / 4
Experimental expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS).
Control expO breast cancer study 1 (lobular carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary lobular carcinoma (NOS) of the breast.

quercetin study 4 (12h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):1.2405138
Number of Samples:3 / 12
Experimental quercetin study 4 (12h)
HepG2 cells exposed to 50μM quercetin in DMSO solvent for 12 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 12 hours.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.2263026
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1326332
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

bisacodyl study 4 (3975ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.0984392
Number of Samples:3 / 17
Experimental bisacodyl study 4 (3975ng/ml)
Bronchial epithelial cells (NHBE) treated with bisacodyl (3975ng/ml; vendor: Prestwick Chemical / catalog number: 419 / catalog name: Bisacodyl [603-50-9]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:, ,
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.0777626
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):-1.0461574
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.